BioCryst Pharmaceuticals’ (BCRX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report released on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 27th. Royal Bank Of Canada cut their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 29th. Finally, JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $20.40.

BioCryst Pharmaceuticals Trading Down 5.9%

NASDAQ:BCRX opened at $8.29 on Tuesday. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.22. The business’s 50-day moving average price is $9.69 and its two-hundred day moving average price is $9.23. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -5.53 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company’s revenue was up 33.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.15 earnings per share. Sell-side analysts predict that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in shares of BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the period. Cetera Investment Advisers increased its stake in BioCryst Pharmaceuticals by 13.8% during the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 1,494 shares during the period. Captrust Financial Advisors raised its holdings in BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 1,527 shares in the last quarter. Legato Capital Management LLC raised its holdings in BioCryst Pharmaceuticals by 10.0% in the 4th quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 2,172 shares in the last quarter. Finally, Creative Planning raised its holdings in BioCryst Pharmaceuticals by 2.6% in the 3rd quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock valued at $672,000 after acquiring an additional 2,280 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.